A Phase 1/2 interventional study of ABI-007 and vinorelbine in Stage IV (Metastatic) Breast Cancer, sponsored by Celgene. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-26.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis — 2 open to participants now, 2 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Neoplasm Metastasis.
Among the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis, this one is the 18th largest by enrollment, is one of 2 that started in 2005, is one of 3 in phase 1/2, and was the 5th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →2 of the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18+
Fudan University · Sites in China
Ages 18–75 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 3
First in 2000; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 56 across the 23 interventional studies. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
50 studies in Neoplasm Metastasis by Bristol-Myers Squibb: 1 open now, 8 under way, 1 of them phase 3. Of 39 finished, 14 (36%) have results posted.
Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 36th largest by enrollment of the 44 interventional ones that give a count, is the only one that started in 2005, is one of 9 in phase 1/2, and was the 12th registered.
Bristol-Myers Squibb’s Neoplasm Metastasis studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 50 in Neoplasm Metastasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to: 1) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support with granulocyte colony-stimulating factor (G-CSF) (Patients with HER-2/neu positive disease may receive Herceptin, and 2) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the presence of planned growth factor support with G-CSF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior irradiation is permitted, provided:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly intravenous infusion of 80 mg/m\^2 ABI-007, followed by an infusion of 15 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
Drug: ABI-007 · Drug: vinorelbine · Drug: Trastuzumab
Weekly intravenous infusion of 80 mg/m\^2 ABI-007, followed by an infusion of 15 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
Drug: ABI-007 · Drug: vinorelbine · Drug: Trastuzumab · Biological: G-CSF
Weekly intravenous infusion of 90 mg/m\^2 ABI-007, followed by an infusion of 20 mg/m\^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
Drug: ABI-007 · Drug: vinorelbine · Drug: Trastuzumab · Biological: G-CSF
Weekly intravenous infusions over 30 minutes.
Also known as: Abraxane®, Nab®-Paclitaxel, paclitaxel protein-bound particles for injectable suspension
Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
Also known as: Navelbine, vinorelbine tartrate, 5'noranhydrovinblastine
Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered. Trastuzumab is commercially available and was not supplied by the Sponsor.
Also known as: Herceptin
During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines. In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg. G-CSF is commercially available and was not supplied by the Sponsor.
Also known as: granulocyte-colony stimulating factor
Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.
Time frame: up to month 30
Participants With Dose Limiting Toxicities
Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Any drug-related toxicities CTC Grade 3 or higher were considered dose limiting. Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death. Other conditions considered dose-limiting toxicities include: * requirement of a dose adjustment during the first 4 weeks * a dose delay of \>3 weeks during the first 4 weeks Grade 3 or greater toxicities attributed to the use of Herceptin were not considered dose-limiting toxicities. The optimal tolerated dose of ABI-007 and vinorelbine given concurrently was defined as the dose administered in the absence of DLTs.
Time frame: up to month 1
Percentage of Participants With Discontinued, Delayed or Interrupted Therapy
Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.
Time frame: up to week 129
Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC), White Blood Cell (WBC), Platelet, and Hemoglobin Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) blood counts were graded using NCI CTCAE version 3. ANC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 1.5\*10\^9/L; Grade 2 = \<1.5 - 1.0\*10\^9/L; Grade 3 = \<1.0 - 0.5\*10\^9/L; Grade 4 = \<0.5\*10\^9/L WBC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L Platelets: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L Hemoglobin: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100 g/L ; Grade 2 = \<100 - 80 g/L; Grade 3 = \<80 - 65 g/L; Grade 4 = \<65 g/L
Time frame: up to week 129 (longest treatment)
Nadir Measurement for Absolute Neutrophil (ANC), White Blood Cell (WBC) and Platelet Count
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.
Time frame: up to week 129 (longest treatment)
Nadir Measurement for Hemoglobin (Hgb)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.
Time frame: up to week 129 (longest treatment)
Percentage of Participants With Stable Disease for >= 16 Weeks, or Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0)
Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
Time frame: up to month 30
Kaplan Meier Estimate for Time to Disease Progression (TTP)
Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: up to month 30
Kaplan-Meier Estimate for Duration of Response
Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: up to month 30
Kaplan Meier Estimate for Progression-Free Survival (PFS)
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Because no patients died as a result of a non-disease progression event, the analysis of PFS was identical to the analysis for TTP.
Time frame: up to month 30
Kaplan-Meier Estimates for Participant Survival
Participant survival is the time from the first dose of study drug to participant death from any cause. Participants that did not die were censored at the last known time the participant was alive.
Time frame: up to 39 months
| Milestone | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Started | 4 | 6 | 6 |
| Completed | 2 | 4 | 4 |
| Not completed | 2 | 2 | 2 |
| Withdrew: Unacceptable toxicity | 1 | 1 | 2 |
| Withdrew: Physician decision | 1 | 1 | 0 |
Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.
| percentage of participants | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Participants With Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) | 25 (0.6 to 80.6) | 16.7 (0.4 to 64.1) | 33.3 (4.3 to 77.7) |
Toxicities were evaluated based on the U.S. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Any drug-related toxicities CTC Grade 3 or higher were considered dose limiting. Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death. Other conditions considered dose-limiting toxicities include: * requirement of a dose adjustment during the first 4 weeks * a dose delay of \>3 weeks during the first 4 weeks Grade 3 or greater toxicities attributed to the use of Herceptin were not considered dose-limiting toxicities. The optimal tolerated dose of ABI-007 and vinorelbine given concurrently was defined as the dose administered in the absence of DLTs.
| participants | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Participants With Dose Limiting Toxicities | 2 | 2 | 2 |
Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.
| percentage of participants | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| At least 1 ABI-007 dose reduction | 50 | 50 | 17 |
| At least 1 Vinorelbine dose reduction | 50 | 50 | 17 |
| At least 1 ABI-007 dose interruption | 0 | 0 | 0 |
| At least 1 Vinorelbine dose interruption | 0 | 0 | 0 |
| At least 1 therapy delay | 75 | 83 | 67 |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) blood counts were graded using NCI CTCAE version 3. ANC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 1.5\*10\^9/L; Grade 2 = \<1.5 - 1.0\*10\^9/L; Grade 3 = \<1.0 - 0.5\*10\^9/L; Grade 4 = \<0.5\*10\^9/L WBC: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L Platelets: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L Hemoglobin: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100 g/L ; Grade 2 = \<100 - 80 g/L; Grade 3 = \<80 - 65 g/L; Grade 4 = \<65 g/L
| participants | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| ANC: grade 0 | 1 | 1 | 3 |
| ANC: grade 1 | 1 | 1 | 0 |
| ANC: grade 2 | 0 | 1 | 0 |
| ANC: grade 3 | 2 | 0 | 1 |
| ANC: grade 4 | 0 | 3 | 2 |
| WBC: grade 0 | 2 | 3 | 1 |
| WBC: grade 1 | 0 | 0 | 1 |
| WBC: grade 2 | 1 | 1 | 2 |
| WBC: grade 3 | 1 | 2 | 2 |
| WBC: grade 4 | 0 | 0 | 0 |
| Platelets: grade 0 | 4 | 4 | 6 |
| Platelets: grade 1 | 0 | 1 | 0 |
| Platelets: grade 2 | 0 | 1 | 0 |
| Platelets: grade 3 | 0 | 0 | 0 |
| Platelets: grade 4 | 0 | 0 | 0 |
| Hemoglobin: grade 0 | 0 | 1 | 0 |
| Hemoglobin: grade 1 | 2 | 0 | 0 |
| Hemoglobin: grade 2 | 1 | 3 | 4 |
| Hemoglobin: grade 3 | 1 | 2 | 2 |
| Hemoglobin: grade 4 | 0 | 0 | 0 |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.
| 10^9/L | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| ANC | 1.74 ± 1.444 | 1.00 ± 0.864 | 1.72 ± 1.589 |
| WBC | 2.79 ± 0.999 | 2.56 ± 0.962 | 2.92 ± 1.572 |
| Platelets | 221.5 ± 108.19 | 187.2 ± 70.35 | 222.7 ± 50.11 |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest observed measurement is the nadir. Blood counts were performed each week of treatment.
| g/L | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Nadir Measurement for Hemoglobin (Hgb) | 89.3 ± 16.11 | 89.7 ± 14.53 | 83.5 ± 6.09 |
Disease control is stable disease (SD) for \>=16 weeks + complete response (CR) + partial response (PR). See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
| percentage of participants | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Disease control | 75 | 66.7 | 33.3 |
| Complete response | 0 | 0 | 0 |
| Partial response | 25 | 17 | 33 |
| Stable disease >=16 weeks | 50 | 50 | 0 |
Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| months | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Kaplan Meier Estimate for Time to Disease Progression (TTP) | 8.8 (1.0 to 30.4) | 7.9 (3.5 to 16.4) | 4.2 (3.5 to 14.5) |
Duration of response is defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Patients that did not have progression or have not died were censored at the last known time the patient was progression free. Patients that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) are defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| months | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Kaplan-Meier Estimate for Duration of Response | 10.4 | 7.9 | 9.6 (4.6 to 14.5) |
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Because no patients died as a result of a non-disease progression event, the analysis of PFS was identical to the analysis for TTP.
| months | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Kaplan Meier Estimate for Progression-Free Survival (PFS) | 8.8 (1.0 to 30.4) | 7.9 (3.5 to 16.4) | 4.2 (3.5 to 14.5) |
Participant survival is the time from the first dose of study drug to participant death from any cause. Participants that did not die were censored at the last known time the participant was alive.
| months | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|---|
| Kaplan-Meier Estimates for Participant Survival | 32.7 (3.1 to 32.7) | 29.2 (25.2 to 29.2) | 22.2 (19.4 to 26.1) |
Collected over Day 1 - up to 133 weeks (longest treatment plus 4 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 80 mg ABI-007 + 15 mg Vinorelbine | — | 5/10 (50%) | 10/10 (100%) |
| 90 mg ABI-007 + 20 mg Vinorelbine | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | 80 mg ABI-007 + 15 mg Vinorelbine | 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 1/6 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/10 | 0/6 |
| BacteraemiaInfections and infestations | 1/10 | 0/6 |
| Catheter related infectionInfections and infestations | 1/10 | 0/6 |
| CellulitisInfections and infestations | 1/10 | 0/6 |
| Cervical myelopathyNervous system disorders | 1/10 | 0/6 |
| Facial nerve disorderNervous system disorders | 1/10 | 0/6 |
| HydropneumothoraxRespiratory, thoracic and mediastinal disorders | 1/10 | 0/6 |
| Event | 80 mg ABI-007 + 15 mg Vinorelbine | 90 mg ABI-007 + 20 mg Vinorelbine |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 8/10 | 6/6 |
| FatigueGeneral disorders | 8/10 | 5/6 |
| AlopeciaSkin and subcutaneous tissue disorders | 5/10 | 5/6 |
| White blood cell count decreasedInvestigations | 8/10 | 3/6 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 8/10 | 2/6 |
| Aspartate aminotransferase increasedInvestigations | 7/10 | 4/6 |
| HypocalcaemiaMetabolism and nutrition disorders | 7/10 | 2/6 |
| HypokalaemiaMetabolism and nutrition disorders | 7/10 | 2/6 |
| Blood alkaline phosphatase increasedInvestigations | 5/10 | 4/6 |
| RashSkin and subcutaneous tissue disorders | 6/10 | 4/6 |
| Age, Customized(participants) | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine | Total |
|---|---|---|---|---|
| < 65 years | 4 ± 5.74 | 5 ± 12.60 | 5 ± 12.23 | 14 |
| >= 65 years | 0 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine | Total |
|---|---|---|---|---|
| Female | 4 | 6 | 6 | 16 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine | Total |
|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 |
| White, Non-Hispanic and Non-Latino | 3 | 5 | 4 | 12 |
| White, Hispanic or Latino | 0 | 1 | 2 | 3 |
| Menopausal Status(participants) | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine | Total |
|---|---|---|---|---|
| Pre-menopausal | 1 | 2 | 1 | 4 |
| Post-menopausal | 3 | 4 | 5 | 12 |
| Smoking Status(participants) | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine | Total |
|---|---|---|---|---|
| Never Smoked | 2 | 4 | 3 | 9 |
| Current Smoker | 1 | 1 | 0 | 2 |
| Previous Smoker, but have Stopped | 1 | 1 | 3 | 5 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Part 1: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 80 mg ABI-007 + 15 mg Vinorelbine | Part 2: 90 mg ABI-007 + 20 mg Vinorelbine | Total |
|---|---|---|---|---|
| Status 0 (Asymptomatic) | 1 | 2 | 1 | 4 |
| Status 1 (Symptomatic but completely ambulatory) | 3 | 4 | 4 | 11 |
| Status 2 (Ambulatory but unable to work) | 0 | 0 | 1 | 1 |
| Status 3 (Limited self-care) | 0 | 0 | 0 | 0 |
| Status 4 (Completely disabled) | 0 | 0 | 0 | 0 |
| Status 5 (Death) | 0 | 0 | 0 | 0 |
The record gives a start of Aug 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Vinorelbine